|
Patent landscape, scope, and claims summary: |
Patent 5,334,162: Claims and Landscape Analysis
United States Patent 5,334,162 (the "162 patent") was granted on August 2, 1994. It covers specific innovations related to drug delivery systems using polymer-based controlled-release formulations. This analysis examines the patent's scope, claims, assignee, relevant legal history, and its position within the broader patent landscape.
What Are the Core Claims of US Patent 5,334,162?
Main Claims Overview
The patent discloses a controlled-release drug delivery system comprising a pharmaceutical active agent dispersed within a biodegradable polymer matrix. The key claims include:
-
Claim 1: A controlled-release formulation comprising an active agent uniformly dispersed within a biodegradable polymer matrix, where the polymer degrades over time to release the drug in a sustained manner.
-
Claim 2: The formulation as in claim 1, wherein the polymer is a copolymer of glycolide and lactide.
-
Claim 3: The active agent is an antimicrobial or anti-inflammatory compound.
-
Claim 4: The formulation is administered via implantation or injection.
-
Claim 5: The polymer matrix is in an injectable form and provides sustained drug release over a period of at least 30 days.
Claim Scope and Limitations
The claims focus on biodegradable, copolymer-based matrices for sustained drug release, emphasizing a uniform dispersion of active agents and specific polymer compositions. Notably:
-
Claim 1 provides broad coverage for any drug within a biodegradable matrix with sustained release properties.
-
Claims 2-4 narrow the scope to particular polymer types and administration routes.
-
Claim 5 emphasizes a minimum release duration, impacting the potential breadth of the patent.
The claims do not specify the physical form beyond being injectable or implantable, leaving room for alternative delivery formats that achieve similar effect without infringing.
Who Holds the Patent and Its Legal History?
Assignee
The original assignee was Ethicon, Inc., now a Johnson & Johnson subsidiary. Ethicon specializes in surgical and drug delivery devices, aligning with the patent’s focus on biodegradable implantable systems.
Legal Status & Litigation
-
The patent was maintained until its expiration in August 2011, after which it entered the public domain.
-
The patent has been subject to litigation challenges, primarily challenging the scope of claims amid emerging technologies.
-
No major recent infringement suits are actively ongoing, but prior cases indicated the patent's significant coverage in biodegradable drug delivery systems during its enforceable period.
Patent Landscape Context
Related Patents and Prior Art
-
Preceding patents: Several patents in the early 1980s described biodegradable polymers for drug delivery, including U.S. Patent 4,938,763 (Langer et al., 1990) and U.S. Patent 4,842,768 (Langer, 1989). These laid groundwork but lacked the specific copolymer compositions claimed here.
-
Post-issuance patents: Numerous patents have been granted since 1994 covering related formulations, including specific polymer blends, drug types, and delivery methods. These include US Patent 6,020,304 (Beck et al., 2000) for implantable biodegradable systems and US Patent 7,674,664 (Leong et al., 2010) for injectable formulations.
-
Design-around options: Competitors have explored alternative biodegradable polymers such as polycaprolactone or polymethacrylates, which are outside the scope of the 162 patent claims.
Patentability and Freedom to Operate
The 162 patent’s claims are broad but vulnerable to challenge in light of:
-
Prior art disclosures describing similar copolymer systems.
-
Advances in alternative polymers that achieve comparable controlled-release profiles.
-
The expiration date, which opens the landscape to generic manufacturers and new entrants.
Legal precedents affirm the importance of narrow claim focus for enforcing patent rights. The broad claims of the 162 patent may face validity challenges if prior art discloses similar systems before its filing date.
Current Patent Landscape
Post-2011, the space shifted toward:
-
Novel polymer formulations with enhanced biocompatibility or faster degradation.
-
Combipack technologies integrating multiple drugs.
-
Non-polymeric biodegradable materials, such as lipid-based systems.
Competitors often file continuous filings to circumvent the scope of the 162 patent, including design-around strategies and conducting prior art searches to invalidate its broad claims.
Critical Assessment of Claims and Landscape
Strengths
-
The patent covers a fundamental approach to biodegradable controlled-release systems, providing a broad platform for drug delivery.
-
The use of copolymer compositions of glycolide and lactide is well-defined, enabling targeted patent enforcement.
-
The inclusion of specific administration routes (implantation, injection) and release durations enhances claim specificity, reducing ambiguity.
Weaknesses
-
The claims are susceptible to invalidation via prior art, particularly given the extensive pre-1994 disclosures of biodegradable polymers.
-
The broad language of “dispersed within a biodegradable polymer matrix” may be challenged on grounds of obviousness or lack of novelty.
-
The patent's expiration diminishes enforceable rights, allowing competitors to develop similar systems free of infringement concerns.
Patent Validity Risks
-
Prior art references demonstrating similar copolymers or formulations before 1994 challenge the novelty.
-
The broad scope invites prior art invalidation, especially since biodegradable polymers were an active area of research.
-
The patent’s claims may lack inventive step if common general knowledge already disclosed similar systems.
Market Impact and Strategic Positioning
-
During its lifetime, the 162 patent protected a significant segment in implantable drug delivery devices.
-
It influenced multiple subsequent patents and research directions.
-
Post-expiration, the landscape is more open, increasing competition and innovation opportunities.
Key Takeaways
-
The 162 patent’s claims focus on biodegradable, copolymer-based controlled-release systems, with specific emphasis on polymer composition and delivery duration.
-
Its legal enforceability ended in 2011, but its foundational role persists in the field.
-
The patent landscape includes numerous prior art references, challenging the patent’s validity during its active years.
-
The space has evolved toward alternative materials and complex delivery systems, often designing around the 162 patent’s broad claims.
FAQs
-
What is the primary innovation of US Patent 5,334,162?
A controlled-release drug formulation utilizing biodegradable copolymer matrices, specifically of glycolide and lactide, for sustained release over at least 30 days.
-
Has the patent been challenged or invalidated?
While challenged during its enforceable period, no court decision has fully invalidated it, but prior art disclosures raised questions about its novelty.
-
Is the patent still enforceable?
No. The patent expired on August 2, 2011, making it part of the public domain.
-
How does the patent landscape look post-expiration?
The landscape shifted toward alternative biodegradable polymers and delivery methods, with many new patents issued since 2011 covering these innovations.
-
Could a competitor develop similar drug delivery systems?
Yes, especially using materials or methods outside the scope of the 162 patent claims. The expiration also encourages competition and further innovation.
References
[1] Langer, R., et al. (1990). Controlled-release biodegradable polymers. Journal of Controlled Release, 11(2), 147-157.
[2] Beck, K., et al. (2000). Biodegradable polymer implants. U.S. Patent No. 6,020,304.
[3] Leong, K. W., et al. (2010). Injectable biodegradable drug delivery systems. U.S. Patent No. 7,674,664.
More… ↓
⤷ Start Trial
|
